HRT Financial’s Xenetic Biosciences XBIO Stock Holding History

HRT Financial’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,747	Closed	-$15K	–	3398
2023 Q1	$15K	Sell	3,747 -1,900	-34%	-$9.22K	﹤0.01%	2212
2022 Q4	$16K	Buy	+5,647	New	+$24.9K	﹤0.01%	2194

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HRT Financial's XBIO Position: Q2 2023 in Review

HRT Financial sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 3,747 shares — an estimated $15K sold.

HRT Financial first reported a position in XBIO in Q4 2022 and held it in 2 quarters. The position peaked at $16K in Q4 2022. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

HRT Financial reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 3,747 Xenetic Biosciences shares in Q2 2023, an estimated $15K.
HRT Financial first reported a position in Xenetic Biosciences in Q4 2022 and held it in 2 quarters.
HRT Financial's Xenetic Biosciences position peaked at $16K in Q4 2022.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.